$CRDF
Cardiff Oncology, Inc. Stock $crdf

$crdf Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000162828020006938 Filed on May 07, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$68.00K	$62.02K
YoY Change	9.64%	-38.06%
Cost Of Revenue		$0.00
YoY Change		-100.0%
Gross Profit		$62.02K
YoY Change		-123.3%
Gross Profit Margin		100.0%
Selling, General & Admin	$1.486M	$1.375M
YoY Change	8.06%	-45.1%
% of Gross Profit		2217.29%
Research & Development	$2.706M	$2.649M
YoY Change	2.17%	40.6%
% of Gross Profit		4270.49%
Depreciation & Amortization	$119.0K	$126.8K
YoY Change	-6.14%	-49.79%
% of Gross Profit		204.42%
Operating Expenses	$4.192M	$4.024M
YoY Change	4.18%	-15.38%
Operating Profit	-$4.124M	-$3.962M
YoY Change	4.1%	-14.89%
Interest Expense	$40.00K	$0.00
YoY Change		-100.0%
% of Operating Profit
Other Income/Expense, Net	-$3.000K	$2.010K
YoY Change	-249.25%	101.0%
Pretax Income	-$4.090M	-$3.900M
YoY Change	4.87%	-18.58%
Income Tax
% Of Pretax Income
Net Earnings	-$4.089M	-$3.905M
YoY Change	4.72%	-18.42%
Net Earnings / Revenue	-6013.24%	-6295.89%
Basic Earnings Per Share		-$1.02
Diluted Earnings Per Share	-$412.7K	-$1.02
COMMON SHARES
Basic Shares Outstanding	10.21M shares	4.087M shares
Diluted Shares Outstanding		4.087M shares

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.300M	$11.30M
YoY Change	-17.7%	68.66%
Cash & Equivalents	$9.277M	$11.33M
Short-Term Investments
Other Short-Term Assets	$900.0K	$900.0K
YoY Change	0.0%	-18.18%
Inventory
Prepaid Expenses	$899.5K	$890.7K
Receivables	$106.4K	$115.7K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$10.28M	$12.34M
YoY Change	-16.65%	57.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$758.5K	$293.4K
YoY Change	158.56%	-86.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$156.4K	$87.07K
YoY Change	79.58%	-74.78%
Total Long-Term Assets	$1.532M	$2.197M
YoY Change	-30.24%	-14.49%
TOTAL ASSETS
Total Short-Term Assets	$10.28M	$12.34M
Total Long-Term Assets	$1.532M	$2.197M
Total Assets	$11.82M	$14.53M
YoY Change	-18.7%	39.63%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$599.0K	$466.7K
YoY Change	28.33%	-28.38%
Accrued Expenses	$3.412M	$2.022M
YoY Change	68.75%	19.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.881M	$3.285M
YoY Change	48.61%	-14.77%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$139.0K	$1.600M
YoY Change	-91.31%	-15.79%
Total Long-Term Liabilities	$139.0K	$1.600M
YoY Change	-91.31%	-15.79%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.881M	$3.285M
Total Long-Term Liabilities	$139.0K	$1.600M
Total Liabilities	$5.672M	$4.847M
YoY Change	17.02%	-15.4%
SHAREHOLDERS EQUITY
Retained Earnings	-$213.0M	-$196.4M
YoY Change	8.46%	10.49%
Common Stock	$8.554K	$7.906K
YoY Change	8.2%	34.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.141M	$9.686M
YoY Change
Total Liabilities & Shareholders Equity	$11.82M	$14.53M
YoY Change	-18.7%	39.63%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$4.089M	-$3.905M
YoY Change	4.72%	-18.42%
Depreciation, Depletion And Amortization	$119.0K	$126.8K
YoY Change	-6.14%	-49.79%
Cash From Operating Activities	-$3.374M	-$3.360M
YoY Change	0.42%	17.48%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$5.274K
YoY Change	-100.0%	3.41%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$5.274K
YoY Change	-100.0%	-47.26%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$1.000M	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.456M	$3.242M
YoY Change	-24.25%	151.34%
NET CHANGE
Cash From Operating Activities	-$3.374M	-$3.360M
Cash From Investing Activities	$0.00	-$5.274K
Cash From Financing Activities	$2.456M	$3.242M
Net Change In Cash	-$918.0K	-$123.1K
YoY Change	646.01%	-92.21%
FREE CASH FLOW
Cash From Operating Activities	-$3.374M	-$3.360M
Capital Expenditures	$0.00	$5.274K
Free Cash Flow	-$3.374M	-$3.365M
YoY Change	0.26%	17.46%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001213037
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2020Q1	trov	Class Of Warrant Or Right Number Exercised ClassOfWarrantOrRightNumberExercised	1005072	shares
CY2020Q1	trov	Class Of Warrant Or Right Number Granted ClassOfWarrantOrRightNumberGranted	931967	shares
CY2019	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P3Y8M21D
CY2020Q1	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P3Y7M0D
CY2019Q4	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	4.08
CY2020Q1	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	4.04
CY2020Q1	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised	1.56
CY2020Q1	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted	0.95
CY2019Q1	trov	Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment	1675000	USD
CY2020Q1	trov	Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment Commonstockpreferredstockandwarrantsissuedinconnectionwithclinicaltrialfundingcommitment	0	USD
CY2019Q1	trov	Costof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment	40000	USD
CY2019Q1	trov	Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock	268269	USD
CY2020Q1	trov	Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock	0	USD
CY2019Q1	trov	Discountof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment	235640	USD
CY2019Q1	trov	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-186689	USD
CY2020Q1	trov	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-206129	USD
CY2019Q1	trov	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-73188	USD
CY2020Q1	trov	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-79796	USD
CY2020Q1	trov	Lessee Operating Lease Annual Rent Increase Percentage LesseeOperatingLeaseAnnualRentIncreasePercentage	0.03
CY2020Q1	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue	1100204	USD
CY2020Q1	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Four LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearFour	3423	USD
CY2020Q1	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Three LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree	5868	USD
CY2020Q1	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Two LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo	676992	USD
CY2020Q1	trov	Lessee Operating Lease Liability Payments Net Of Sublease Income Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear	413921	USD
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12303274	shares
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	Trovagene, Inc.
CY2019Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	4127	USD
CY2020Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2020	USD
CY2019Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6060	USD
CY2020Q1	us-gaap	Dividends Preferred Stock DividendsPreferredStock	6060	USD
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.02
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2019Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
CY2020Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3635	USD
CY2020Q1	trov	Lessor Number Of Subleases LessorNumberOfSubleases	2	lease
CY2019Q1	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	6060	USD
CY2020Q1	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	6060	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	88283	USD
CY2019Q1	trov	Release Of Clinical Trial Funding Commitment ReleaseOfClinicalTrialFundingCommitment	70487	USD
CY2020Q1	trov	Release Of Clinical Trial Funding Commitment ReleaseOfClinicalTrialFundingCommitment	293017	USD
CY2019Q1	trov	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	70487	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-52079	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-97048	USD
CY2020Q1	trov	Releaseofclinicaltrialfundingcommitmentforservicesreceived Releaseofclinicaltrialfundingcommitmentforservicesreceived	293017	USD
CY2020Q1	trov	Sale Of Stock Value Common And Warrants Net SaleOfStockValueCommonAndWarrantsNet	-1000001	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-15725	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1206	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
CY2019Q4	trov	Servicereceivable Servicereceivable	971673	USD
CY2020Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	10676	USD
CY2020Q1	trov	Servicereceivable Servicereceivable	678656	USD
CY2019Q1	trov	Servicereceivable Servicereceivable	1675000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-179691	USD
CY2019Q1	trov	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	3282266	USD
CY2020Q1	trov	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	1456369	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-55506	USD
CY2019Q1	us-gaap	Interest Income Operating InterestIncomeOperating	64743	USD
CY2020Q1	us-gaap	Interest Income Operating InterestIncomeOperating	35823	USD
CY2019Q1	us-gaap	Lease Cost LeaseCost	13655	USD
CY2020Q1	us-gaap	Lease Cost LeaseCost	33951	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1609757	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	656304	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	598985	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3423	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	203480	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	106432	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5868	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	968165	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	632301	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	89544	USD
CY2020Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2020Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10516377	shares
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	trov	Lessee Operating Lease Monthly Rent Payment LesseeOperatingLeaseMonthlyRentPayment	78000	USD
CY2020Q1	trov	Lessee Operating Lease Number Of Renewal Options LesseeOperatingLeaseNumberOfRenewalOptions	1	renewal_option
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3260061	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3411723	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2604293	USD
CY2020Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2723613	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	217172528	USD
CY2020Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	219805965	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	200067	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	177309	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	200067	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	177309	USD
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3735269	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11496978	shares
CY2019Q4	us-gaap	Assets Assets	13086546	USD
CY2020Q1	us-gaap	Assets Assets	11815403	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	11353729	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	10282908	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10195292	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9277025	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11453133	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11330079	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10195292	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9277025	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-123054	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-918267	USD
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10589482	shares
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2020Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8593633	shares
CY2020Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11010587	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3831880	shares
CY2020Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6436505	shares
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	8312	USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	8554	USD
CY2019Q2	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	333333	shares
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	126781	USD
CY2020Q1	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	509553	USD
CY2020Q1	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	0	USD
CY2020Q1	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	0	USD
CY2020Q1	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	291173	USD
CY2019Q4	us-gaap	Liabilities Liabilities	5775202	USD
CY2020Q1	us-gaap	Liabilities Liabilities	5671985	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	119320	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13086546	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11815403	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4781744	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4881300	USD
CY2020Q1	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	218380	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	4191710	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3961763	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4124006	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3242266	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2456370	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5274	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3360046	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3374637	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3904771	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-4088562	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4179100	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4094622	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4179100	USD
CY2020Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4094622	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	4023784	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	113592	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	106744	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1726342	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1520213	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	865379	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	870592	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	860963	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	649621	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	226364	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	233078	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	697418	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	617622	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y0M0D
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y9M4D
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	157576	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	156370	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	128368	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	139044	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2010	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2486	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5274	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2019Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
CY2020Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3482116	USD
CY2020Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3482116	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	877823	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	758503	USD
CY2020Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2020Q1	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	954957	USD
CY2020Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	899451	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1000001	USD
CY2019Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-40000	USD
CY2020Q1	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2019Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3282266	USD
CY2020Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1456369	USD
CY2019Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2648599	USD
CY2020Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2705691	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-208897883	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-212992505	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	62021	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	67704	USD
CY2019Q1	us-gaap	Revenues Revenues	62021	USD
CY2020Q1	us-gaap	Revenues Revenues	67704	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1375185	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1486019	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	200067	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	177309	USD
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	188984	USD
CY2020Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	34929	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-40000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	10084192	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	9686181	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	7311344	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	6143418	USD
CY2019Q1	us-gaap	Sublease Income SubleaseIncome	99937	USD
CY2020Q1	us-gaap	Sublease Income SubleaseIncome	72793	USD
CY2019Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-9761	USD
CY2020Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	2107	USD
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	4086561	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9910306	shares

Files In Submission

Name	View Source	Status
0001628280-20-006938-index-headers.html	Edgar Link	pending
0001628280-20-006938-index.html	Edgar Link	pending
0001628280-20-006938.txt	Edgar Link	pending
0001628280-20-006938-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trov-033120exhibit311.htm	Edgar Link	pending
trov-033120exhibit312.htm	Edgar Link	pending
trov-033120exhibit321.htm	Edgar Link	pending
trov-033120exhibit322.htm	Edgar Link	pending
trov-033120x10q.htm	Edgar Link	pending
trov-20200331.xml	Edgar Link	completed
trov-20200331.xsd	Edgar Link	pending
trov-20200331_cal.xml	Edgar Link	unprocessable
trov-20200331_def.xml	Edgar Link	unprocessable
trov-20200331_lab.xml	Edgar Link	unprocessable
trov-20200331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRDF
Cardiff Oncology, Inc. Stock $crdf

2020 Q1 Form 10-Q Financial Statement

#000162828020006938 Filed on May 07, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF Cardiff Oncology, Inc. Stock $crdf

2020 Q1 Form 10-Q Financial Statement

#000162828020006938 Filed on May 07, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF
Cardiff Oncology, Inc. Stock $crdf